SP
ABBV icon

Saranac Partners’s AbbVie ABBV Stock Holding History

Saranac Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
41,086
+6,525
+19% +$1.4M 3.02% 8
2026
Q1 		$7.46M Sell
34,561
-4,682
-12% -$1.04M 3.19% 9
2025
Q4 		$8.98M Buy
39,243
+8,164
+26% +$1.86M 3.51% 7
2025
Q3 		$7.16M Buy
31,079
+2,794
+10% +$569K 1.3% 16
2025
Q2 		$5.25M Sell
28,285
-2,641
-9% -$491K 2.79% 12
2025
Q1 		$6.48M Sell
30,926
-1,011
-3% -$197K 3.68% 4
2024
Q4 		$5.68M Buy
31,937
+1,158
+4% +$213K 3.13% 9
2024
Q3 		$6.08M Sell
30,779
-2,626
-8% -$490K 9.17% 3
2024
Q2 		$5.73M Buy
33,405
+1,274
+4% +$211K 3.41% 7
2024
Q1 		$5.85M Sell
32,131
-3,198
-9% -$551K 3.58% 5
2023
Q4 		$5.47M Sell
35,329
-19,468
-36% -$2.84M 3.61% 6
2023
Q3 		$8.17M Buy
54,797
+335
+0.6% +$49.2K 4.59% 5
2023
Q2 		$7.34M Buy
54,462
+5,371
+11% +$788K 3.89% 8
2023
Q1 		$7.82M Buy
49,091
+33,349
+212% +$5.1M 4.61% 2
2022
Q4 		$2.54M Buy
+15,742
New +$2.41M 4.61% 4

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Saranac Partners's ABBV Position: Q2 2026 in Review

Saranac Partners increased its AbbVie (ABBV) stake by 19% in Q2 2026, buying an estimated $1.4M and bringing the position to 41,086 shares worth $10.4M. The position accounts for 3.02% of the portfolio, ranked #8.

Saranac Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Saranac Partners held 41,086 shares of AbbVie worth $10.4M as of Q2 2026.
  • Saranac Partners bought 6,525 AbbVie shares in Q2 2026, an estimated $1.4M.
  • AbbVie made up 3.02% of Saranac Partners's portfolio in Q2 2026, its #8 holding.
  • Saranac Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Saranac Partners's 13F filing for Q2 2026, filed 13 Aug 2026.